Johnson & Johnson trades above 21x forward EPS with $24B in Q3 revenue, and a raised FY25 sales guidance outlook. Read why JNJ stock is downgraded to hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback